奥扎格雷,Ozagrel

奥扎格雷|T6236

价格 145 297 493
包装 1mg 5mg 10mg
最小起订量 1mg
发货地 上海
更新日期 2026-01-06
QQ交谈 微信洽谈

产品详情

中文名称:奥扎格雷英文名称:Ozagrel
CAS:82571-53-7品牌: TargetMol
产地: 美国保存条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
产品类别: 抑制剂
货号: T6236
2026-01-06 奥扎格雷 Ozagrel 1mg/145RMB;5mg/297RMB;10mg/493RMB 145 TargetMol 美国 Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. 抑制剂

Product Introduction

Bioactivity

名称Ozagrel
描述Ozagrel (Domenan) is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
激酶实验In vitro kinase assays: The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.
体内活性Ozagrel (3 mg/kg) decreases both the area and volume of the cortical infarction after ischemia-reperfusion of the middle cerebral artery in rat. Ozagrel also has suppressive effects on the neurologic deficits in the microthrombosis rat model. Ozagrel improves the reduced spontaneously locomotor activity and the obstruction of motor coordination in the conscious cerebral ischemia-reperfusion mouse model. Ozagrel prevents oleic acid (OA)-induced thromboxane A(2) generation and subsequently increased total protein concentration and the numbers of macrophages and neutrophils in bronchoalveolar lavage fluid and increases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in the whole lung of guinea pigs. Ozagrel suppresses the decrease in specific gravity of the brain tissue induced by the occlusion-reperfusion in the conscious cerebral ischemia-reperfusion SHR model, and recovers the postischemic decrease in cortical PO(2) after middle cerebral artery occlusion-reperfusion in cats. Ozagrel administered intravenously 30 min before oleic acid injection prevents the decrease in Pao(2) and pulmonary vascular hyper-permeability in guinea-pigs. Ozagrel also prevents increases in lactate dehydrogenase activity, a measure of lung cell injury, TXB(2) and its weight ratio to 6-keto prostaglandin F(1alpha) in bronchoalveolar lavage fluid in guinea-pigs. Ozagrel also increases the level of 6-keto-PGF(1alpha), a metabolite of prostaglandin I(2) (PGI(2)), in the brain tissue after cerebral ischemia-reperfusion, and the administration of PGI(2) improves the reduced spontaneous locomotor activity in the conscious cerebral ischemia-reperfusion mouse model.
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
溶解度Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (4.38 mM), Sonication is recommended.
DMSO : 2.29 mg/mL (10.03 mM), Sonication is recommended.
关键字TXA2 | Thromboxane A2 synthetase | thromboxane A2 | ProstaglandinReceptor | Prostaglandin Receptor | platelet | Ozagrel | OKY046 | OKY 046 | Inhibitor | inhibit | antiplatelet | aggregation
相关产品Evodiamine | Dabigatran Etexilate Mesylate | Heparin sodium salt | Lornoxicam | p-Hydroxycinnamic acid | (S)-(+)-Ibuprofen | Rebamipide | Ethamsylate | Tranilast | Dabigatran etexilate | Pranoprofen | AEBSF hydrochloride
相关库抑制剂库 | 经典已知活性库 | 抗癌上市药物库 | 已知活性化合物库 | 抗衰老化合物库 | GPCR靶点分子库 | 免疫/炎症分子化合物库 | 膜蛋白靶向化合物库 | 疼痛相关化合物库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库
关键字: 奥扎格雷|||OKY-046|||Domenan|TargetMol

公司简介

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起,为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部,化学事业部,生物事业部和新材料部。 从虚拟筛选到实体化合物分子供应;从商业化产品销售到个性化定制合成;从对明确靶点的分子筛选到对明确分子的多靶点筛选,从高通量筛选到化学结构优化,我们都可以满足您的科研用品及技术服务的需求。 经过在中国市场五年的精心耕耘,我们已成为筛选化合物领域优秀的供应商,为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛
成立日期 2013-04-18 (13年) 注册资本 566.2651万人民币
员工人数 100-500人 年营业额 ¥ 1亿以上
主营行业 化学试剂,生物活性小分子 经营模式 贸易,试剂,定制,服务
  • TargetMol中国(陶术生物)
VIP 13年
  • 公司成立:13年
  • 注册资本:566.2651万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:小分子抑制剂,药物筛选化合物库,天然产物,活性分子化合物等
  • 公司地址:上海市闸北区江场三路28号4楼
询盘

店内推荐

奥扎格雷|T6236相关厂家报价

更多
产品名称 价格   公司名称 报价日期
¥249
VIP1年
湖北源梦生物科技有限公司
2026-01-08
询价
VIP9年
山东诚汇医药集团有限公司
2026-01-08
询价
VIP10年
济南晟齐医药科技有限公司
2026-01-08
询价
VIP7年
湖北摩科化学有限公司
2026-01-08
询价
VIP10年
湖北威德利化学科技有限公司
2026-01-08
询价
VIP10年
武汉维斯尔曼生物工程有限公司
2026-01-08
¥548
VIP5年
湖北魏氏化学试剂股份有限公司
2026-01-08
询价
VIP4年
湖北魏氏化学试剂股份有限公司
2026-01-08
询价
VIP12年
四川省维克奇生物科技有限公司
2026-01-07
询价
VIP4年
湖北海克斯生化有限公司
2025-12-29
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.